ATCC

ATCC is heading to BioProcess International 2025 in Boston. Our team can’t wait to connect with fellow innovators, researchers, and industry leaders at booth #1615. Stop by to explore our latest breakthroughs in: 🔬 Microbial QC testing with MicroQuant™ 🧫 Biologics production 🛡️ Safety testing 🧬 Cell & gene therapy development 💉 Vaccine development Plus, don’t miss our Fireside Chat with Dr. Nilay Chakraborty on Sept 18 at 3:00 PM where he will dive into next-gen analytical technologies and the future of microbial quality control. We’re excited to meet you, share ideas, and help accelerate your bioprocessing goals. Learn more: https://ow.ly/LUXI50WJK3w #BPIconf

This stunning drone footage captures the scale and ambition of a project that will advance global health and scientific discovery. The new Biomanufacturing facility at our Manassas, VA headquarters will play a key role in supporting the US bioeconomy and biomanufacturing by providing a long-term US-based manufacturing source of critical biological standards and reagents for global health issues.   🔬 From groundbreaking to building the future of life science—this is what progress looks like.

Dr. Randall Kincaid highlights how ATCC played an important role in responding to the Zika crisis. Learn more about how our trusted and credible resources have led to incredible results over the years. https://ow.ly/P3jI50WJEF3

Are you attending the WC13 conference in Rio de Janeiro, Brazil? Be sure to stop by our poster by Carolina Lucchesi and learn how colorectal cancer organoid-on-a-chip models offer a physiologically relevant platform for drug sensitivity testing by replicating the tumor microenvironment and enabling real-time compound delivery.

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, remains the leading cause of death from infectious diseases worldwide, responsible for nearly 1.5 million fatalities each year. While TB primarily affects humans, several closely related bacterial species cause similar diseases in animals; these include M. africanum, M. bovis, M. caprae, M. microti, and M. pinnipedii. Collectively, these organisms are classified within the Mycobacterium tuberculosis Complex (MTBC), a group historically thought to consist of distinct species based on host range and subtle phenotypic differences. However, ATCC scientists, led by Dr. Marco Riojas, recently challenged this long-standing classification. By applying advanced genomic tools—specifically whole-genome sequencing (WGS), digital DNA-DNA hybridization (dDDH), and comprehensive phylogenomic analysis—the team examined the type strains of each MTBC member. Their findings revealed that these so-called species are not genetically distinct enough to warrant separate species status. Instead, they are best understood as closely related host-adapted variants of Mycobacterium tuberculosis. To validate this conclusion, the researchers extended their analysis to over 3,700 non-type MTBC genome sequences available in GenBank. The results were consistent: all strains fell within the genetic boundaries of M. tuberculosis. This discovery not only resolved a long-standing taxonomic ambiguity but also underscored the importance of genome-based classification in modern microbiology. The findings were published in the International Journal of Systematic and Evolutionary Microbiology, officially unifying the previously separate members of the MTBC under a single species name: Mycobacterium tuberculosis. The previous species name or lineage is not lost, however, as we recommended that this be used as the variant name, e.g., Mycobacterium tuberculosis var. BCG (ATCC® 35743 ™). ATCC also hosted a webinar describing these research findings. This reclassification has significant implications for diagnostics, epidemiology, and our broader understanding of TB evolution and host adaptation. Learn more: https://ow.ly/Kyrh50WJSav Read our blog: https://ow.ly/m91b50WJSar #100for100

Join us on September 4, 2025 at 12:00 PM ET for our upcoming webinar: Combating Antimicrobial Resistance: How ATCC’s AMR Collection Supports the Global Scientific Community Discover how our curated collection of 100 phenotypically and genomically characterized AMR strains is helping researchers worldwide tackle one of the most urgent public health threats. Register now: https://ow.ly/rx3O50WMftl

Check out our latest blog post to learn about our curated, high-resolution dataset capturing gene expression profiles across a diverse panel of lung cancer cell lines. Read the blog: https://ow.ly/epY650WJSrj #CredibleConversations

Only a few days left to vote for BioSpace’s 2026 Best Places to Work. Make sure to cast your vote for ATCC in the small company category by Sunday, August 31 at the following link: https://ow.ly/b8PS50WJKxv

The CDC reports that since 1997, more than 890 sporadic human infections with highly pathogenic avian influenza (HPAI) H5N1 have been reported globally. These cases, often linked to direct contact with infected poultry, highlight the zoonotic potential of avian influenza viruses. In the U.S., the 2014–2015 outbreaks of H5N2 and H5N8 led to the largest poultry epidemic in national history. For over a century, ATCC has been a trusted global resource for authenticated biological materials, playing a critical role in pandemic preparedness and infectious disease research. To support research and response efforts, ATCC provides standardized viral strains—such as H1N1 A/PR/8/34—and human cell lines like Calu-3, which are essential for studying viral replication, host-pathogen interactions, and transmissibility. These tools have enabled scientists to conduct reproducible studies that inform vaccine development, antiviral testing, and public health strategies. As H5N1 continues to circulate in wild birds, poultry, and even spill over into mammals, ATCC remains a cornerstone of global health infrastructure—empowering researchers to detect, understand, and respond to emerging threats with speed and scientific rigor. Learn more: https://ow.ly/uQM850WJPnq Read our blog: https://ow.ly/vkOF50WJPnp #100for100

We are currently in a pandemic—the seventh cholera pandemic since 1817. Cholera is caused by the ingestion of water/food contaminated with the bacterium Vibrio cholerae and symptoms include watery diarrhea, vomiting, leg cramps, and restlessness. Worldwide, there are an estimated 1-4 million cases and 21-143 thousand deaths from cholera each year. V. cholerae is a gram-negative motile bacterium with a distinctive curved morphology and a single polar flagellum. The bacterium expresses multiple virulence factors, most notably Cholera toxin, toxin-coregulated pilus (TCP), multiple secretion systems, flagella, and accessory toxins. Interestingly, the predominant strain in the seventh pandemic is a V. cholerae biotype called “El Tor,” which is genetically distinct from the “Classical” biotypes that caused pandemics 1-6; these distinctions are the focus of much of the research today. Despite its prevalence, cholera is a preventable and highly treatable disease. Prevention relies on access to safe drinking water, early detection and treatment, and improved health care infrastructure.23 A majority of people infected will show no or mild symptoms, but severe infections can be treated with rehydration solutions and antibiotics.21,23 The prevention of cholera within London in the 19th century significantly contributed to the understanding and acceptance of Germ Theory. There was an outbreak of cholera in London in 1854 during the third cholera pandemic and Dr. John Snow thought that instead of the Miasma Theory (bad air), the spread of infection was caused by contaminated water sources (Germ Theory). As the story goes, he convinced the authorities to remove the handle of the Broad Street pump, which stopped the residents from consuming water from the suspected source of the infection. Within a few days the spread of the disease stopped, and Dr. Snow would continue to study and decrease the spread of cholera in subsequent outbreaks throughout the city. These studies led to the development of modern epidemiology, and the broad street pump map is still used in classrooms today. ATCC contains >65 strains of V. cholerae, including “Classical” biotypes, “El Tor” biotypes, knock-out strains, and more to help further study and create mitigation strategies to combat this organism. Learn more: https://ow.ly/yO2k50WJP8T Read our blog: https://ow.ly/WOl750WJP8W #100for100